Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42

Archives of Neurology

Volumn 60, Issue 9, 2003, Pages 1202-1206

  Maddalena, Alessia ^a   Papassotiropoulos, Andreas ^a   Müller Tillmanns, Britta ^a   Jung, Hans H ^b   Hegi, Thomas ^a   Nitsch, Roger M ^a   Hock, Christoph ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOCHEMICAL MARKER; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CALCULATION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES, MONOCLONAL; APOLIPOPROTEINS E; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PROTEIN-SERINE-THREONINE KINASES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0042972779     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.9.1202     Document Type: Article

References (25)

1. Growdon JH. Biomarkers of Alzheimer disease. Arch Neurol. 1999;56:281-283.
2. Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer's disease: a clinicopathologic study. Arch Neurol. 1996;53:35-42.
3. Papassotiropoulos A, Hock C. Biochemical markers of Alzheimer's disease: wish and reality. Neurobiol Aging. 2002;23:513-514.
4. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 1999;52:1555-1562.
5. Sjogren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;70:624-630.
6. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol. 2001;24:87-97.
7. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39(pt 1):1159-1165.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
9. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57:416-418.
10. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050-1058.
11. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies - report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
13. Nauck M, Hoffmann MM, Wieland H, Marz W. Evaluation of the apo E genotyping kit on the LightCycler. Clin Chem. 2000;46:722-724.
14. Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging. 1989;29:307-335.
15. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
16. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61:1828-1834.
17. Hock C, Golombowski S, Naser W, Muller-Spahn F. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol. 1995;37:414-415.
18. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643-648.
19. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937-945.
20. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373-379.
21. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40 and Aβ1-42(43). Ann Neurol. 1998;44:17-26.
22. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol Aging. 1998;19:109-116.
23. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59:1729-1734.
24. Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand. 1993;88:221-223.
25. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease [review]. Neurobiol Aging. 1997;18(suppl 4):S1-S2.